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Summary NAD(P)H:quinone oxidoreductase (NQO1, EC 1.6.99.2) is an obligate two-electron reductase that can either bioactivate or
detoxify quinones and has been proposed to play an important role in chemoprevention. We have previously characterized a homozygous
point mutation in the BE human colon carcinoma cell line that leads to a loss of NOO1 activity. Sequence analysis showed that this mutation
was at position 609 of the NQO1 cDNA, conferring a proline to serine substitution at position 187 of the NQO1 enzyme. Using polymerase
chain reaction (PCR) analysis, we have found that the H596 human non-small-cell lung cancer (NSCLC) cell line has elevated NQO1 mRNA,
but no detectable enzyme activity. Sequencing of the coding region of NQO1 from the H596 cells showed the presence of the identical
homozygous point mutation present in the BE cell line. Expression and purification of recombinant wild-type and mutant protein from E. coli
showed that mutant protein could be detected using immunoblot analysis and had 2% of the enzymatic activity of the wild-type protein. PCR
and Northern blot analysis showed moderate to low levels of expression of the correctly sized transcript in the mutant cells. Immunoblot
analysis also revealed that recombinant mutant protein was immunoreactive; however, the mutant protein was not detected in the cytosol of
either BE or H596 cells, suggesting that the mutant proteins were either not translated or were rapidly degraded. The absence of any
detectable, active protein, therefore, appears to be responsible for the lack of NQO1 activity in cells homozygous for the mutation. A
polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis for the mutation at position 609 conducted on 90
human lung tissue samples (45 matched sets of tumour and uninvolved tissue) revealed a 7% incidence of individuals homozygous for the
mutation, and 42% heterozygous for the mutation. These data suggest that the mutation at position 609 represents a polymorphism in an
important xenobiotic metabolizing enzyme, which has implications for cancer therapy, chemoprevention and chemoprotection.
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NAD(P)H:quinone oxidoreductase (NQO1) is an obligate two-
or four-electron reductase that plays a role in protection against
natural and xenobiotic quinones. Compounds such as butylated
hydroxyanisole, butylated hydroxytoluene, Oltipraz and extracts of
cruciferous vegetables, such as green onions andbroccoli, are potent
inducers ofNQO1 (Wattenberg, 1985; Prochaska et al, 1992; Zhang
et al, 1992; Enger et al, 1994). These chemicals have been shown to
protect against toxicity, mutagenesis or carcinogenesis, suggesting
that induction ofNQOI may play a major role in cytoprotection and
chemoprevention (Wattenberg, 1985). Paradoxically, NQOI can
also activate anti-tumour quinones, such as mitomycin C, E09,
streptonigrin and diaziquone, via the production of redox labile
hydroquinones orreactive alkylating agents generated by rearrange-
ment after reduction by the enzyme (Siegel et al, 1990; Walton and
Workman, 1990; Gibson et al, 1992, 1994; Ross et al, 1993; Beall et
al, 1994). NQO1 is expressed in many human tissues, and NQOI
levels have been shown tobe elevated in lung, colon, liverandbreast
cancer tissues compared with uninvolved tissue from the same
origin (Schlager and Powis, 1990; Malkinson et al, 1992).
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In 1980, Edwards etal, showedthatNQOl was lacking in 4% of
a British population (Edwards et al, 1980). We characterized a
point mutation in the BE colon carcinoma cell line that led to a loss
of enzymatic activity consistent with the absence of enzymatic
activity observed in the previous studies (Traver et al, 1992).
Sequencing analysis revealed a homozygous C to Tpoint mutation
at position 609 of the NQO1 cDNA, which conferred a proline to
serine substitution at position 187 of the NQO1 protein. This was
the first mutation identified in the coding region ofNQOl, and we
suggested that it was responsible for the lack ofNQO1 activity in
these cells. Although BE cells have recently been reported to be
heterozygous for the C to T mutation atposition 609 by Kuehl et al
(1995), their status as homozygous mutants has been confirmedby
collaborative studies in the two laboratories involved (Ross et al,
1996). NQO1 has also been shown to be absent in both normal
and cancerous tissues of three out of 23 (13%) renal carcinoma
patients, and these three individuals were all homozygous for the
mutant allele (Eickelmann et al, 1994a,b). Marshall et al character-
ized a lack of NQO1 activity in fibroblasts form a cancer-prone
family and made the suggestion that deficient NQO1 activity may
predispose to cancer (Marshall et al, 1991a,b). Rosvold et al
(1995a) have subsequently used single-strand conformation poly-
morphism (SSCP) analysis to show that the mutant allele occurred
with a frequency of 0.13 in a reference population. The data
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suggest that the mutation at position 609 represents a polymor-
phism in a drug-metabolizing enzyme. The functional significance
of this polymorphism, as well as its occurrence in the population
as a homozygous or heterozygous trait, however, remains unclear.
Recently, we found that the H596 non-small-cell lung cancer
(NSCLC) cell line had moderate levels ofNQOI gene expression
but no detectable enzymatic activity (Traver et al, 1995). In this
manuscript, we show the presence of the identical C to T point
mutation present in the BE cells in the coding region of H596
cells. Using PCR, Northern and immunoblot analysis, we have
examined the effects ofthe homozygous C to T point mutation on
the production of NQOI. Additionally, we have screened 90
human lung samples from both normal and paired tumourtissue to
elucidate the incidence of this mutation at position 609 more
clearly. These findings have implications forchemoprevention and
for the treatment of cancers with drugs that require bioreductive
activation by NQO1.
MATERIALS AND METHODS
Cell lines
Cells were grown as monolayers at 37°C in minimum essential
medium (Gibco, BRL) supplemented with 10% fetal bovine serum
(FBS; Gibco, BRL), penicillin (10 units ml-'), streptomycin (10units
ml-'), L-glutamine (2 mM) and non-essential amino acids (0.1 M).
Analysis of N01 enzymatic activity
Cells were grown to 80% confluence before being washed with
Hanks' balanced salt solution and scraped into ice-cold buffer
[25 mm Tris-HCl (pH 7.4) and 125 mm sucrose]. A cell sonicate
was then made for each cancer cell line by sonicating the cell
suspension for 30 s on ice. NQO1 activity ofthe cell sonicates was
then assayed according to Ermster (1967), as modified by Benson et
al (1980). Reactions (0.5 ml) were performed at 25°C in the pres-
ence and absence of0.02 mm dicoumarol in a buffer containing 25
mM Tris-HCl (pH 7.4), 0.7 mg ml-' bovine serum albumin (BSA),
0.2 mm NADH and 0.04 mm dichlorophenolindophenol (DCPIP).
NQO1 activity was measured as the dicoumarol-sensitive reduc-
tion of DCPIP (e 21 000 M-l cm-') measured by the decrease in
absorbance at 600 nm in a Shimadzu UV16OU spectrophotometer.
Protein content in the cell sonicates was assayed by the method of
Bradford (1976).
RNA extraction and cDNA synthesis
RNA was extracted fiom cell cultures using the method described
by Peppel and Baglioni (1990). All cells were in the exponential
phase of the growth curve at the time of RNA extraction. RNA
pellets were dissolved in DEPC-treated water and immediately
reverse transcribed. The reverse transcription reaction contained
20gl of 5 x reverse transcription buffer (Gibco BRL), 10 ,ul of
dNTPs (10 mm, Pharmacia), 2.5 p1 of RNAasin (40 U pl-', Pro-
mega), 0.5 gl of random hexamers (18 U ml-', Pharmacia), 10 pl
of dithiothreitol (0.1 M, Gibco BRL), 400 U of MMLV reverse
transcriptase (Gibco BRL) and 55 gl of RNA(7.5-10 ,ug). The
reaction was incubated at 37°C for 1 h followed by heating to
95°C for S min. The quantity ofRNA extracted was determined by
absorbance readings at 260-280 nm and reference to a calibration
curve generated using yeast tRNA (Sigma).
Quantitation of NQ01 expression by PCR
NQO1 expression was determined using a semi-quantitative
reverse transcription-PCR technique, details of which are
described elsewhere (Phillips et al, 1993). To 1 pl of cDNA in a
sterile 0.5 ml centrifuge tube, 8 pl of a master mix consisting
of 1 pl of 10 x PCR buffer (Promega), 1 pl of dNTPs (0.5 mm,
Pharmacia), 0.8 pl of magnesium chloride (25 mM, Promega), 0.1
pl [aC32P]dATP (3000 Ci mmol-', NEN), 0.05 pl ofTaq DNA poly-
merase (5000 U ml-', Promega) and 5.05 pl ofdeionized water was
added. To each tube, 1 pl ofprimers (7.5 mM) was added and the
complete reaction mix was overlayed with light mineral oil
(Sigma). All steps were performed on ice. Thermal cycling condi-
tions following an initial denaturation at 95°C for 1 min were: 30 s
at 95°C, annealing at 65°C for 30 s and extension at 72°C for 30 s.
At the end of25 cycles, samples were incubated at 72°C for 5 min.
Amplified products were separated on a 5% polyacrylamide gel
and the products were visualized by autoradiography. Radio-
activity incorporated into amplified products was determined by
scintillation counting of the excised bands. Gene expression was
calculated as the ratio between the slope for the target gene to the
slope for the endogenous internal standard gene, with each slope
being obtained from regression analysis of the linear region of
amplification. Theprimers used foramplification were synthesized
on aBiosystems model 391 PCR-MATE DNA synthesizer with the
following sequences:
NQO1 (target gene)
Sense: 5'-AGAAGAGCACTGATCGTACTGG-3'
Antisense: 5'-CGTAATTGTAAGCAAACTCTCCTATG-3'
,B-actin (internal standard gene)
Sense: 5'-CCACGAAACTACCTTCAACTCC-3'
Antisense: 5'-TCATACTCCTGCTGCTTGCTGATCC-3'
Northern analysis of NQ01 transcripts
Total RNA (10 jg) isolated from cell cultures was denatured by
incubation for 1 h at 50°C in 50% dimethyl sulphoxide (DMSO)
and 17% deionized glyoxal. The denatured RNA was then sepa-
rated on a 1.5% agarose gel and transferred to a Duralon-UV
(Stratagene) membrane. RNA was cross-linked to the membrane
with UV light and hybridized for 12 h at 650C with 0.5M sodium
dihydrogen phosphate (pH 7), 1 mM EDTA, 1% BSA and 7%
sodium dodecyl sulphate (SDS). Radiolabelled probe was gener-
ated using 25 ng of double-stranded DNA comprising the coding
region of NQOl using the Random Priming DNA labelling kit
(BRL) and 5 p1 of [a32P]dATP (3000 Ci mmol-', NEN). The blot
was washed three times in 2 x saline sodium citrate (SSC)
0.1% SDS and exposed to Kodak XAR film. The blot was
stripped by boiling in 0.1 x SSC and reprobed with the coding
region of the I-actin gene. Autoradiographs were quantitated by
laser densitometry using ,B-actin mRNA as a standard.
Sequencing and cloning of the NQ01 coding region
The coding region from thewild-type H460 cells and the mutant BE
andH596 cells was sequencedby amplification ofaliquots ofcDNA
fromthese cell lines. The resulting double-stranded DNA fragments
were then denatured and sequenced with Sequenase II (USB).
The NQO1 coding region from the wild-type H460 cells and the
mutant BE and H596 cells was amplified using an antisense
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primer that included a 5'HindIII cut site and a sense primer span-
ning the naturally occurring NcoI cut site immediately 5' to the
start codon. The resulting PCR product was then cut with HindIII
and NcoI and ligated into pKK233-2. The resulting vector was
transformed into JM109 E. coli for amplification and purification.
Purification of recombinant NQ01
E. coli expressing either wild-type or mutant NQO1 proteins
were grown to log phase in the presence of 2 mmisopropyl-o-D-
thiogalactopyranside. A 50-g pellet of these cells was then soni-
cated on ice in 25 mM Tris HCL, pH 7.4, containing 125 mM
sucrose, and centrifuged at 100 000 g for 90 min. The resulting
supematant was examined for NQO1 protein expression by
immunoblot analysis (see below). No NQOl protein was detected
in untransformed E. coli; however, NQO1 protein was detected in
E. coli transformed with the coding region from both wild-type
(H460) and mutant (BE, H596) cells. Wild-type and mutant
NQO1 proteins were purified from the supernatant by Cibacron
blue affinity chromatography as describedpreviously (Sharkis and
Swenson, 1989). Purified wild-type and mutant NQO1 proteins
were both resolved as a single band on 12% sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) with a
molecular mass of 30 kDa. Purified wild-type and mutant NQO1
proteins had a FAD to protein monomer ratio of approximately
1:1 (Faeder and Siegel, 1973). Enzyme activity of the purified
G A T C
C to T mutation
at position 609
Figure 1 DNA sequencing of the NQO1 coding region from H596 cells.
Arrow indicates the homozygous point mutation at position 609 of the NQO1
coding region
recombinant proteins was assayed using dicoumarol-sensitive
DCPIP reduction as described above.
Immunoblot analysis and N-terminal sequencing
E. coli cytosols, H460, H596 and BE cell cytosols and purified
wild-type and mutant NQO1 proteins were examined by immuno-
blot analysis for reactivity against a mouse monoclonal antibody
(B771) raised against wild-type (H460) NQO1 in our laboratory
or a polyclonal antibody (gift from Dr G Powis, University of
Arizona, USA). The proteins were first separated by 12% SDS-
PAGE and then transferred to nitrocellulose in 10 mm Tris, 192
mM glycine containing 20% methanol at 35 V for 14 h. Following
transfer, the nitrocellulose was blocked with 1% BSA for 1 h and
then 20 ml of B771 hybridoma tissue culture media was added
for 1 h followed by a goat antimouse IgG-alkaline phosphatase
conjugate (1:5000) for 30 min. Visualization was performed with
BCIP/NBT.
N-terminal sequencing was carried out on purified recombinant
wild-type and mutant NQO1 proteins following 12% SDS-PAGE
and transfer to PVDF membrane. N-terminal sequencing was
performed at the Protein Sequencing Core Facility, University of
Colorado Health Sciences Center. The N-terminal sequence for
H460- and BE-derived NQO1 proteins was consistent with the
previously published sequence for human liver NQO1 (Jaiswal
et al, 1988).
PCR-RFLP analysis of DNA samples for the mutation
PCR products were generated using 1 gg of genomic DNA
extracted from matched tumour and normal lung biopsies from
lung cancer patients. These PCR products were examined for the
presence of the mutation using an RFLP assay developed by
Eickelmann et al (1994b) with the following modifications. The
sense primer (5' TCCTCAGAGTGGCATTCTGC-3') and anti-
sense primer (5'-TCTCCTCATCCTGTACCTCT-3') amplified a
211-bpregion, including the last sevenbases ofexon 5 andthe first
204bases ofintron 6. Thermal cycling conditions were fourcycles
of 94°C for 15 s, 69°C for 15 s and 720C for 30 s; eight cycles of
94°C for 15 s, 67°C for 15 s, and 72°C for 30 s; and 29 cycles of
94°C for 30 s, 65°C for 30 s, and 72°C for 1 min. The PCR prod-
ucts generated were digested with 36 units ofHinfl for5 h at 37°C
and separated on a 1.5% agarose gel containing 0.5 gg mln-
Table I NOO1 expression vsenzymatic activity in nine lung cancer cell lines
Cell line Cell type Gene expression Enzymatic actIvityab
H460 NSCLC 1010 501 (1502)
A549 NSCLC 785 392 (1176)
UCLC11 NSCLC 278 230 ( 690)
H520 NSCLC 150 77 ( 231)
H596 NSCLC 47 ND
H661 NSCLC 29 26 ( 79)
H446 SCLC 10 4 ( 12)
H146 SCLC 8 3 ( 10)
H82 SCLC 1 1 ( 3)
aND, not detectable (<1 nmol min-' mg-' protein). bValues in parentheses are
actual enzymatic activity expressed as nmol DCPIP min-' mg-' protein. For
clarity, values are expressed relative to the H82 cells. Gene expression and
enzymatic activity were measured as described in Materials and methods.
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Figure 2 Northern blot analysis of NQ01 transcripts in (A) colon and (B) lung cancer cell lines. Arrows indicate the expected 1.2-, 1.7- and 2.7-Kb NQ01
transcripts. In each case, the blot was reprobed with ,-actin as an internal control as described in Materials and methods
ethidium bromide. H460 and either H596 or BE cells were used
as controls for wild-type and homozygous mutants respectively.
Of the lung cancer patients, 37 (82%) were Caucasian, ranging
in age from 33 to 81 years, five 5 (11%) were Hispanic aged
60-68 years and three (7%) were African-American, aged 54-65
years. Of the 45 patients, 37 (82%) were male and eight (18%)
were female.
RESULTS
We compared NQO1 gene expression and enzymatic activity in
a panel of small-cell lung cancer (SCLC) and NSCLC cell lines
(Table 1). This analysis resulted in a good correlation (r = 0.97)
between gene expression and enzymatic activity in these lung
carcinoma cells. H596 NSCLC cells, however, fell notably outside
this correlation with moderate NQOI gene expression, but almost
no enzymatic activity. To determine whether this discrepancy was
also caused by a mutation in the coding region of the NQOI gene,
the cDNA from these cells was cloned and sequenced revealing
the identical homozygous C to T point mutation (Figure 1) that we
characterized as being responsible for the lack ofNQOI activity in
BE human colon carcinoma cells. We had previously reported in
abstract form (Traver et al, 1995) that the H596 cells had an addi-
tional A to T point mutation at position 790 of the cDNA. After
sequencing of the cDNA from H596 cells, it appears that this
mutation was generated during PCR amplification and subcloning
and is not present in native H596 cDNA.
Northern analysis of N01 transcripts
Northern analysis was used to confirm the presence and size ofthe
NQO1 transcript in cell lines containing the mutation. The NQOI
transcript has four polyadenylation sites in the 3' untranslated
region (Jaiswal, 1991). Three of these sites are used to produce
transcripts 1.2 kb, 1.7 kb and 2.7 kb in size. Northern analysis
revealed NQOI transcripts in BE and H596 cells, which were
identical in size to the transcripts present in wild-type cells from
the tissue ofthe same origin (Figure 2).
Immunoblot analysis of N01 proteins
Immunoblot analysis was used to verify the presence and size of
the NQO1 proteins from E. coli and human cell lines expressing the
mutant NQO1 genes. Figure 3 shows an immunoblot comparing
NQOI proteins in cytosol or recombinant proteins purified from
E. coli. Lane 1 contains the recombinant H460 wild-type protein
purified from E. coli and lane 2 contains the cytosol from the H460
NSCLC cell line, which expresses the wild-type NQO1. Lane 3
contains cytosol from the H596 cells, which does not show any
detectable NQO1 protein. Similarly, lane 4 contains the recombi-
nant, mutant protein purified from E. coli expressing the coding
region from the BE colon carcinoma cell line, which has the proline
to serine substitution, and lane 5 contains cytosol from the BE cells.
Again, the mutant NQO1 protein is absent in the cytosol from cells
that are homozygous for the C to T point mutation at position 609.
Identical data demonstrating an absence of NQO1 protein in H596
and BE cells have also been obtained using a polyclonal antibody
to NQOl (data not shown).
Enzymatic activity of recombinant N01 proteins
In order to examine the activity of the mutant NQOI protein, the
coding region of NQO1 from the H460 cells expressing the wild-
type protein, as well as the coding region from the BE colon carci-
noma cells, were expressed in E. coli and purified as described in
Materials and methods. Purified recombinant NQOI from E. coli
expressing the wild-type protein had a specific activity averaging
645 ,umol min-'mg-' protein. The specific activity of the purified
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Figure 3 Immunoblot analysis of purified recombinant NQO1 proteins and
NQO1 expression in tumour cells. Immunoblot analysis was performed on
purified recombinant NQO1 proteins (0.1 jug) and tumour cell sonicates (25
ig). Reaction conditions are described in Materials and methods. Lane 1,
recombinant H460 NQO1 protein; lane 2, H460 cell sonicate; lane 3, H596
cell sonicate; lane 4, recombinant BE NQO1 protein; lane 5, BE cell sonicate
protein from cells expressing the coding region from the BE cell
line, which contains the homozygous C to T point mutation at
position 609, produced aprotein with 2% ofthe specific activity of
the wild-type recombinant protein.
Frequency of the C to T point mutation
To clarify the prevalence of the C to T point mutation at position
609 of the NQO1 cDNA, a PCR-RFLP analysis was used to
screen tumour and uninvolved tissue from 45 lung cancer patients
ranging in age from 33 to 81 years. Normal tissue samples from
these patients included uninvolved lung tissue or blood samples
from these individuals. Table 2 shows the results ofthis screening.
A total of 51% of the lung cancer samples were homozygous for
the wild-type protein, while 42% were heterozygous for the muta-
tion and 7% were homozygous for the mutation.
Histologically, the tumour tissues examined were composed of
squamous cell cancers, adenocarcinomas, small-cell and large-cell
lung cancers, bronchioalveolar cancers, a carcinoid tumour and an
adenosquamous cancer. Tumour samples homozygous forthe muta-
tion included a carcinoid tumour and two adenocarcinomas with
bronchioalveolar components. Tumour samples heterozygous for
the mutant allele were composedprimarily ofsquamous cell cancers
(45%) and adenocarcinomas (40%) with one small-cell lung cancer
and one adenosquamous cancer. Tumour samples homozygous for
the wild-type allele were composed of48% squamous cell cancers,
28% adenocarcinomas, 12% small-cell lung cancers, 8% bron-
chioalveolar cancers and one large-cell lung cancer.
DISCUSSION
The enzymatic activities of the recombinant proteins presented
here show that the purified recombinant NQOl protein carrying
the proline to serine substitution at amino acid 187 has only 2% of
the enzymatic activity of the wild-type enzyme. In our previous
work, we speculated that the proline to serine substitution in the
NQOI enzyme could adversely affect the pyridine nucleotide-
binding site ofthe enzyme. Subsequently, Ma et al (1992) demon-
strated that the glycine residue atposition 150, the serine residue at
position 151 and the tyrosine residue at position 155 ofthe NQOI
protein were essential for pyridine nucleotide binding, and that the
tyrosine at position 128 was important for dicoumarol binding.
This suggests that the pyridine nucleotide-binding site may be
unaffected by the loss of the proline residue at position 187. The
crystal structure of the rat enzyme published recently by Li et al
(1995) has defined the binding sites for both pyridine nucleotide
and quinone substrates. This work indicates extensive overlap
between these binding sites and confirms that both binding sites
are not directly affected by the proline substitution at position 187.
The crystal structure indicates that the proline at position 187 is
located at the end ofabeta sheet and is adjacent to an exposed loop
(Li et al, 1995). A mutation at this position may, therefore, cause
structural alterations in this area and compromise loop stability.
The effects of the proline to serine substitution at position 187 on
protein structure are, therefore, unclear at present but obviously
have profound consequences on the activity ofNQO1. It is impor-
tant to stress that, although aheterozygous C to T mutation at posi-
tion 609 may be associated with widely differing NQO1 activities
(Kuehl et al, 1995), ahomozygous C to T mutation results in a lack
ofNQOl protein and activity.
The human NQO1 gene is composed of six exons separated by
five introns and is located on chromosome 16. The last exon has
four polyadenylation sites, three of which are used, giving rise to
1.2 kb, 1.7 kb and 2.7 kb transcripts (Jaiswal, 1991). PCR analysis
showed that the NQOl gene is transcribed at moderate levels, and
ourNorthern analysis showed transcripts ofthe correct size in cells
that are homozygous or heterozygous for the mutation. This
suggests that the NQOI gene is successfully transcribed and
appropriately spliced in cells containing the mutation.
Immunoblot analysis of recombinant and cytosolic NQOl
proteins showed that the recombinant enzyme containing the C to
T mutation atposition 609 can be expressed in E. coli, purified and
detected using immunoblots. Our data show that the mutant
protein is of the correct molecular weight but almost completely
dysfunctional as indicated by activity assays. In addition to the
recombinant wild-type protein, the NQO1 enzyme is detectable on
immunoblot analysis in the cytosol of the H460 cells, which
express the functional NQO1 gene. The mutant enzyme expressed
in E. coli is also detectable by immunoblot analysis; however,
the cytosol from both H596 and BEcells, which carry the homozy-
gous C to T mutation, did not contain any detectable NQOl
Table 2 Frequency of the C to T point mutation in 45 lung cancer patients stratified by sex and race
Tumour Normal Male Female Caucasian Hispanic African-American
tissue tissue
Total 45 45 37 8 37 5 3
Wild-type 23 (51) 23 (51) 19 (51) 4 (50) 19 (51) 3 (60) 1 (33)
Heterozygous 19 (42) 19 (42) 17 (46) 2 (25) 15 (41) 2 (40) 2 (67)
Homozygous mutant 3 ( 7) 3 ( 7) 1 ( 3) 2 (25) 3 (18) 0 ( 0) 0 ( 0)
Tumour tissue and uninvolved tissue (either lung or blood) was tested from each patient as described in Materials and methods. Numbers indicate individual
tissue samples, which were homozygous for the wild-type NOO1 gene, heterozygous for the mutation (heterozygous) or homozygous for the mutation
(homozygous mutant). Numbers in parenthesis indicate the percentage of samples in each group.
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enzyme using both immunoblot and activity assays. This experi-
ment was performed using both monoclonal and polyclonal anti-
bodies to NQOI. Therefore, although activity studies show the
purified mutant proteins have detectable but very low activity, our
data suggest that reason for the lack ofenzymatic activity in cells
homozygous for the C to T point mutation at position 609 is owing
to an absence ofNQO1 protein.
Recently Rosvold et al (I995a) detected the same C to T substi-
tution at position 609 in a Centre d'Etude Polymorphisme Humain
(CEPH) reference panel composed of 82 parents and additional
family members. The mutant allele appeared in the CEPH panel
with a frequency of 0.13 in a manner consistent with Mendelian
inheritance. This group tested the association of this mutation
with lung cancer, and their preliminary evidence suggested that
the mutant allele was over-represented in lung cancer cases.
Preliminary data discussed in a recent exchange of letters was
conflicting with respect to an increased prevalence of the NQOI
polymorphism in patients with colon cancer (Rosvold et al, 1995b;
Kolesar et al, 1995). The data we present here show a frequency of
7% ofboth tumour and normal tissue samples homozygous for the
mutation, while 42% of the samples were heterozygous for the
mutation. The presence ofthe mutation in matched lung and blood
samples suggests that, in these patients, the mutation is neither
tissue nor tumour specific, but represents a true polymorphism.
Polymorphisms have been established in numerous phase I and
phase II metabolic enzymes (Gonzalez and Idle, 1994). Examples
include many members of the cytochrome P450 family of meta-
bolic enzymes, as well as oxidases, reductases and esterases.
Polymorphisms in phase II metabolic enzymes include sulpho,
acetyl, methyl and glutathione transferases. These polymorphisms
are associated with significant alterations in response and suscepti-
bility to xenobiotics (Caporaso et al, 1991). We have shown that
NQOI is important in protection against benzene-derived
quinones (Ross et al, 1990; Ganousis et al, 1992). In very recent
work, we have demonstrated that workers with the NQOI poly-
morphism are at increased risk of benzene-induced decreases
in white blood cell count relative to matched controls (Rothman
etal, 1996).
A polymorphism leading to a lack of NQO1 activity is of
special significance in that the enzyme acts as a protective
measure against oxidative damage produced by a wide range of
naturally occurring and xenobiotic quinones, which undergo
redox cycling subsequent to two-electron reduction by NQOI
(Prochaska et al, 1992; Zhang et al, 1992; Enger et al, 1994). A
lack of NQOI may have implications for both chemoprotection
and chemoprevention. Indeed, the potential benefit of chemopre-
ventive agents, which act through the induction of NQO1, could
be significantly decreased in populations homozygous for this
mutation. Additionally, the presence of this polymorphism
presents significant problems in the exploitation of the elevated
NQOI activity of certain tumours by administering anti-tumour
quinones, which require bioreductive activation. In an attempt to
predict the clinical response of tumours to these drugs, it has been
suggested that NQOI expression in tumour samples could be eval-
uated by PCR before drug treatment. The presence ofthis mutation
would lead to tumour types that are unresponsive to these drugs,
despite apparent elevated NQO1 gene expression as detected by
PCR. As such, it will be necessary to confirm the absence of the
mutation at position 609 using PCR-RFLP analysis or, more
importantly, the presence of NQOI activity in these samples for
studies of this kind to be successful.
In summary, we have characterized a proline to serine mutation
in NQOI, which results in a complete loss of enzyme activity.
Although purified mutant NQOI had only 2% of wild-type
activity, the lack of enzyme activity appears to be caused by a
complete absence of NQOI protein. The presence of the homozy-
gous mutation in matched lung and blood samples suggests that
this mutation represents a true polymorphism and was found to be
present in 7% of 45 matched sets of human lung tumours and
paired uninvolved tissue. These results may have implications for
cancer therapy, chemoprotection and chemoprevention.
ABBREVIATIONS
NQO1, NAD(P)H:quinone oxidoreductase 1; NSCLC, non-
small-cell lung cancer; SCLC, small-cell lung cancer; PCR,
polymerase chain reaction; RFLP, restriction fragment length
polymorphism.
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